Dr. Aman Gebremedhin, MD

Dr. Gebremedhin practices at Johns Hopkins Howard County Medical Center in Columbia, Maryland, part of Johns Hopkins Health System.

Dr. Gebremedhin's NPI, 1558742510, was assigned on June 16, 2015. Dr. Gebremedhin holds Maryland license D85751.

Dr. Gebremedhin's primary practice is Johns Hopkins Howard County Medical Center, at 5755 Cedar Lane, Columbia, MD 21044 in Howard County. The practice phone is (410) 740-7890.

Dr. Gebremedhin's primary practice is Johns Hopkins Howard County Medical Center in Columbia, Maryland, part of Johns Hopkins Health System. Dr. Gebremedhin is also affiliated with University of Maryland Baltimore Washington Medical Center. The medical group on file is Emergency Medicine Physicians (EMP). Dmand AI also links Dr. Gebremedhin to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gebremedhin practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Gebremedhin's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dmand AI has Dr. Gebremedhin's licenses on file in 2 states: Maryland and Pennsylvania.

CMS data shows 907 Medicare services from Dr. Gebremedhin across 4 procedure codes in 2024, for 314 Medicare patients. Medicare paid $76,472 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 314 Medicare patients who saw Dr. Gebremedhin in 2024. The largest group is 85 and over, with 116 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 24% are also on Medicaid. Their average risk score is 2.47, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gebremedhin's median patient age at 78, with 57% women.

In 2024, Dr. Gebremedhin wrote 142 Medicare Part D claims for 79 patients. 89% of them were for generic drugs. CMS names the drug for 26 of them, across 2 drugs with 11 or more claims each, at $122 in total drug cost. In 2023, CMS named 24 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Gebremedhin for performance year 2024, reported as part of a group. Dr. Gebremedhin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 1 general payment to Dr. Gebremedhin from 1 drug or device company in 2022. Food and beverage make up the largest share, 100% of the total. Abbvie Inc. paid the most, $20.